Last reviewed · How we verify
Heartburn
Approved treatments
- Tagamet
- Bss · B Braun
ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) SOLUTION A prevents blood clotting by binding free calcium, a crucial co-factor in the clotting cascade. - Gaviscon · Sanofi
- Renacidin · United Guardian
- Milk of Magnesia · Generic (multiple manufacturers)
- Zantac · GSK (originally Glaxo)
- Pepcid · Generic (originally Yamanouchi/Merck)
Competitively blocks histamine H2 receptors on gastric parietal cells, reducing basal and stimulated acid secretion. - Gaviscon · Sanofi
- carbaldrate
Carbaldrate works by reducing stomach acid production. - Gelusil
- Potassium Alum · Novartis Pharmaceuticals
- Ultra Strength Antacid · Target Corporation
- Alka-Seltzer Gold · Bayer HealthCare LLC.
- Axid Ar
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Heartburn patent landscape — cliff calendar, originator estates, attackable patents
- Heartburn treatment landscape brief
- Heartburn treatment updates RSS
Frequently asked questions about Heartburn
What drugs treat Heartburn?
Tracked treatments include Tagamet, Bss, Gaviscon, Renacidin, Milk of Magnesia, Zantac, Pepcid, carbaldrate.
What is the treatment for Heartburn?
Standard treatment for Heartburn includes Tagamet, Bss, Gaviscon, Renacidin, Milk of Magnesia. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Heartburn patent cliff · Heartburn CI report
- Treatment: Tagamet
- Treatment: Bss · B Braun
- Treatment: Gaviscon · Sanofi
- Treatment: Renacidin · United Guardian
- Treatment: Milk of Magnesia · Generic (multiple manufacturers)
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing